New And Special Drugs
-
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-
Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
-
Exdensur (Depemokimab) – Eosinophilic Asthma | HongKong DengYue Medicine
-
Zometa (Zoledronic Acid) – HCM | HongKong DengYue Medicine
-
Taltz (Ixekizumab) – Plaque Psoriasis | HongKong DengYue Medicine
-
Megace (Megestrol Acetate) – Anorexia | HongKong DengYue Medicine
-
Adempas (Riociguat) – CTEPH/PAH | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as PD-1/PD-L1 and CTLA-4, and have become a cornerstone of modern
Belantamab Mafodotin Approved in China for Multiple Myeloma: First-in-Class BCMA ADC Marks New Milestone
On April 17, China’s National Medical Products Administration (NMPA) approved belantamab mafodotin in combination with bortezomib and dexamethasone for the treatment of adult patients with
Top 5 Global Neuroscience Pharma Companies: Core Products and Pipeline Analysis
Neuroscience (CNS) has long been regarded as one of the most challenging areas in the pharmaceutical industry, due to long development timelines, high failure rates,
Sevabertinib Approved in China for HER2-Mutant NSCLC: A New Oral Targeted Therapy Option
On April 15, Bayer announced that its innovative targeted therapy Hyrnuo® (sevabertinib, BAY 2927088) has been officially approved by the National Medical Products Administration. ✨
HCC First- and Second-Line Treatment Updates: What’s New in Current Guidelines
To further improve the standardization of diagnosis and treatment for primary liver cancer, the newly released 2026 guideline introduces important HCC first- and second-line treatment
What Are the Top 5 Autoimmune Diseases to Watch in 2026? Insights into Immunotherapy Trends and Innovation
Over the past decade, autoimmune diseases have remained one of the most stable and high-growth areas in global drug innovation. From TNF-α inhibitors to IL-17/IL-23
China Pharmaceutical Export Trends and Global Pharmaceutical Market Opportunities
China’s pharmaceutical industry is undergoing a profound structural transformation, and China pharmaceutical export trends are also changing significantly. From a past dominated by active pharmaceutical
Oral GLP-1 Drug Development Trends: Small-Molecule Innovation and Industry Competition
In recent years, GLP-1 receptor agonists (GLP-1 RAs) have become one of the most closely watched therapeutic areas in the global metabolic disease landscape. Among
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
